• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纳多法基因菲拉地诺韦克 - vncg对药剂师的实际应用。

Practical use of nadofaragene firadenovec-vncg for pharmacists.

作者信息

Holler Seth D, Smith Sara Moran

机构信息

WVU Medicine, Morgantown, WV, USA.

Allina Health, Minneapolis, MN, USA.

出版信息

J Oncol Pharm Pract. 2025 Apr;31(3):488-494. doi: 10.1177/10781552251315146. Epub 2025 Feb 17.

DOI:10.1177/10781552251315146
PMID:39962875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11986079/
Abstract

ObjectiveTo provide a practical approach to pharmacists regarding the safe and effective use of nadofaragene firadenovec.Data sourcesClinical study data and pharmacist experience in institutional settings.Data summaryThis review article discusses the role of pharmacists caring for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) receiving nadofaragene firadenovec. Pharmacist roles in a multidisciplinary care team are described and involve considerations surrounding nadofaragene firadenovec, including its mechanism of action, indication, handling, storage, administration, adverse event profile, disposal, counseling, and other practical points.ConclusionsPharmacists are positioned to be key contributors to the care team regarding the effective use of nadofaragene firadenovec. Further awareness and education will continue to optimize the clinical use of nadofaragene firadenovec in the high-risk BCG-unresponsive NMIBC setting.

摘要

目的

为药剂师提供一种关于安全有效使用纳多福基因法瑞地诺韦的实用方法。

数据来源

临床研究数据以及机构环境中药剂师的经验。

数据总结

这篇综述文章讨论了药剂师在护理接受纳多福基因法瑞地诺韦治疗的卡介苗（BCG）无反应性非肌肉浸润性膀胱癌（NMIBC）患者中的作用。描述了药剂师在多学科护理团队中的角色，包括围绕纳多福基因法瑞地诺韦的考虑因素，如其作用机制、适应症、处理、储存、给药、不良事件概况、处置、咨询以及其他实际要点。

结论

药剂师有能力成为护理团队中有效使用纳多福基因法瑞地诺韦的关键贡献者。进一步提高认识和开展教育将继续优化纳多福基因法瑞地诺韦在高风险BCG无反应性NMIBC环境中的临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b39/11986079/3e9927a816ea/10.1177_10781552251315146-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b39/11986079/3e9927a816ea/10.1177_10781552251315146-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b39/11986079/3e9927a816ea/10.1177_10781552251315146-fig1.jpg

相似文献

1
Practical use of nadofaragene firadenovec-vncg for pharmacists.纳多法基因菲拉地诺韦克 - vncg对药剂师的实际应用。
J Oncol Pharm Pract. 2025 Apr;31(3):488-494. doi: 10.1177/10781552251315146. Epub 2025 Feb 17.
2
Clinical use of nadofaragene firadenovec-vncg.纳多法基因菲拉地诺韦克 - vncg的临床应用。
Ther Adv Urol. 2024 Sep 17;16:17562872241280005. doi: 10.1177/17562872241280005. eCollection 2024 Jan-Dec.
3
Nadofaragene Firadenovec: First Approval.那度鲁胺：首次批准
Drugs. 2023 Mar;83(4):353-357. doi: 10.1007/s40265-023-01846-z.
4
Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies.纳多法基因菲拉地诺维c-vncg的安全性：2期和3期研究数据综述
Can J Urol. 2025 Mar 18;32(1):29-36. doi: 10.32604/cju.2025.064710.
5
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.评估 nadofaragene firadenovec-vncg 治疗高危卡介苗无应答性非肌肉浸润性膀胱癌。
Expert Opin Biol Ther. 2024 Jun;24(6):415-423. doi: 10.1080/14712598.2024.2365802. Epub 2024 Jun 13.
6
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.美国食品药品监督管理局批准摘要：用于卡介苗无反应性非肌肉浸润性膀胱癌的纳多法基因菲拉地诺韦克 - vncg
Clin Cancer Res. 2025 Apr 1;31(7):1182-1185. doi: 10.1158/1078-0432.CCR-24-2812.
7
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.膀胱内注射纳多福基因菲拉地诺韦治疗卡介苗无反应性非肌层浸润性膀胱癌患者的疗效：一项3期试验的5年随访
J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5.
8
Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.卡介苗免疫治疗无应答的非肌肉浸润性膀胱癌中纳武利尤单抗联合富马酸奈达那非的成本效果分析。
Value Health. 2023 Jun;26(6):823-832. doi: 10.1016/j.jval.2022.12.005. Epub 2022 Dec 16.
9
Mechanism of action of nadofaragene firadenovec-vncg.纳多法基因菲拉地诺韦克 - vncg的作用机制。
Front Oncol. 2024 Mar 15;14:1359725. doi: 10.3389/fonc.2024.1359725. eCollection 2024.
10
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.抗腺病毒抗体预测 Nadofaragene Firadenovec 治疗卡介苗无应答性非肌肉浸润性膀胱癌的反应持久性：III 期临床试验的二次分析。
Eur Urol. 2022 Mar;81(3):223-228. doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18.

本文引用的文献

1
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.膀胱内注射纳多福基因菲拉地诺韦治疗卡介苗无反应性非肌层浸润性膀胱癌患者的疗效：一项3期试验的5年随访
J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Mechanism of action of nadofaragene firadenovec-vncg.
纳多法基因菲拉地诺韦克 - vncg的作用机制。
Front Oncol. 2024 Mar 15;14:1359725. doi: 10.3389/fonc.2024.1359725. eCollection 2024.
4
Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?年龄与非肌层浸润性膀胱癌的关联：能否揭示流行病学差异的生物学基础？
Eur Urol Oncol. 2024 Oct;7(5):1069-1079. doi: 10.1016/j.euo.2024.01.011. Epub 2024 Feb 1.
5
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.非肌层浸润性膀胱癌的诊断与治疗：美国泌尿外科学会/泌尿外科学会指南：2024年修订版
J Urol. 2024 Apr;211(4):533-538. doi: 10.1097/JU.0000000000003846. Epub 2024 Jan 24.
6
The effect of polypharmacy on healthcare services utilization in older adults with comorbidities: a retrospective cohort study.多药治疗对共病老年患者医疗服务利用的影响：一项回顾性队列研究。
BMC Prim Care. 2023 May 26;24(1):120. doi: 10.1186/s12875-023-02070-0.
7
Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.卡介苗无反应性非肌层浸润性膀胱癌患者的治疗偏好：一项跨国选择实验
Eur Urol Open Sci. 2023 Jan 31;49:92-99. doi: 10.1016/j.euros.2022.12.016. eCollection 2023 Mar.
8
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
9
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
10
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.非肌层浸润性膀胱癌的人文及经济负担：两项系统文献综述的结果
Clinicoecon Outcomes Res. 2020 Nov 23;12:693-709. doi: 10.2147/CEOR.S274951. eCollection 2020.